Meet CBP

Jun Shao is responsible for overseeing the company's operations in the US, regulatory submissions and registrations, GMP and GCP quality assurance systems, clinical drug supply and logistics, later-stage product pipeline development. Prior to joining the company, Dr. Shao held R&D and Management positions in several US and Chinese leading pharmaceutical companies, including Abbott laboratories, Procter and Gamble Pharmaceuticals, eVenus Pharmaceutical Laboratories (Jiangsu Hengrui's US subsidiary), and Zhejiang Hisun Pharmaceutical. With over 30 years of academic and industry experiences in China and the US, Dr. Shao has a strong background in drug research and development, manufacturing, regulatory affairs, and quality assurance. He has successfully filed over a dozen of IND/ANDA submissions with the US FDA and led passing numerous regulatory GMP inspections by Chinese NMPA, US FDA, EMA, WHO and Health Canada.

Ms. Tang has more than 30 years of experience in finance and investment management. She is a versatile and senior investor with expertise spanning the primary market, public funds, commercial banks, and industrial mergers & acquisitions. She excels in deeply integrating industrial thinking, capital operation, and government resources, with a focus on the healthcare sector, where she pursues long-term value investment and industrial ecosystem empowerment. Ms. Tang has served as a partner at Sanze Ventures and Yicun Capital. She has also held management positions at several renowned financial institutions, including Harfor Fund, Franklin Templton Sealand Fund, and Agricultural Bank of China. Currently, she acts as an independent director of Holitech Technology Co., Ltd (002217.SZ). Ms. Tang holds a Bachelor's Degree in Literature from Central South University and a Master's Degree in Economics from Huazhong University of Science and Technology.